Literature DB >> 30205885

Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction.

Tariq Jamal Siddiqi1, Muhammad Shariq Usman1, Muhammad Shahzeb Khan2, JayaKumar Sreenivasan3, Ibrahim Kassas4, Haris Riaz5, Sajjad Raza6, Salil V Deo7, Hasanat Sharif8, Ankur Kalra6, Neha Yadav9.   

Abstract

ST-elevation myocardial infarction patients presenting at non-percutaneous coronary intervention (PCI)-capable hospitals often need to be transferred for primary percutaneous coronary intervention (PPCI). This increases time to revascularization, leading to increased risk of in-hospital mortality. With recent focus on total ischemic time rather than door-to-balloon time as the principal determinant of outcomes in ST-elevation myocardial infarction patients, pharmacoinvasive therapy (PIT) has gained attention as a possible improvement over PPCI in patients requiring transfer. Our objective was to observe how PIT stands against PPCI in terms of safety and efficacy. Electronic databases were searched for randomized controlled trials and observational studies comparing PPCI to PIT. PIT was defined as administration of thrombolytic drugs followed by immediate PCI only in case of failed thrombolysis. Results from studies were pooled using a random-effects model. We identified 17 relevant studies (6 randomized controlled trials, 11 observational studies) including 13,037 patients. Overall, there was no significant difference in short-term mortality (odds ratio [OR] = 1.20 [0.97 to 1.49]; I2 = 14.2%; p = 0.099); however, PIT significantly decreased short-term mortality (OR = 1.46 [1.08 to 1.96]; I2 = 0%; p = 0.01) in those studies with a symptom-onset-to-device time ≥200 minutes. There was a significantly lower risk reinfarction (OR = 0.69 [0.49 to 0.97]; I2 = 0%; p = 0.033) in the PPCI group, while the risk of cardiogenic shock was significantly higher (OR = 1.48 [1.13 to 1.94]; I2 = 0%; p = 0.005). In conclusion, PIT versus PPCI decisions should preferably be customized in patients presenting to non-PCI capable hospitals. Factors that need to be considered include symptom-onset to first medical contact time, expected time of transfer to a PCI-capable hospital, and patients risk factors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30205885     DOI: 10.1016/j.amjcard.2018.04.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country.

Authors:  Manuel Chacón-Diaz; Piero Custodio-Sánchez; Paol Rojas De la Cuba; Germán Yábar-Galindo; René Rodríguez-Olivares; David Miranda-Noé; Luis Marcos López-Rojas; Akram Hernández-Vásquez
Journal:  BMC Cardiovasc Disord       Date:  2022-06-29       Impact factor: 2.174

2.  Management strategies and outcomes of acute coronary syndrome (ACS) during Covid-19 pandemic.

Authors:  Mingliang Zuo; Shoubo Xiang; Sanjib Bhattacharyya; Qiuyi Chen; Jie Zeng; Chunmei Li; Yan Deng; Chungwah Siu; Lixue Yin
Journal:  BMC Cardiovasc Disord       Date:  2022-05-25       Impact factor: 2.174

3.  Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy.

Authors:  Kaiyin Li; Bin Zhang; Bo Zheng; Yan Zhang; Yong Huo
Journal:  Front Cardiovasc Med       Date:  2022-03-17

4.  Clinical Competence in ST-segment Elevation Myocardial Infarction Management by Recently Graduated Physicians Applying for a Medical Residency Program.

Authors:  Ugo Stocco Aimoli; Carlos Henrique Miranda
Journal:  Arq Bras Cardiol       Date:  2020-01       Impact factor: 2.000

5.  Collaborative Heart Attack Management Program (CHAMP): use of prehospital thrombolytics to improve timeliness of STEMI management in British Columbia.

Authors:  Andrew Guy; Nicki Gabers; Chase Crisfield; Jennie Helmer; Shaylee C Peterson; Anders Ganstal; Caryl Harper; Ross Gibson; Sumandeep Dhesi
Journal:  BMJ Open Qual       Date:  2021-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.